In subjects with Dry Eye Syndrome (DES):
The primary objective of this study is to confirm the efficacy of TOP1630 0.1% Ophthalmic
Solution TID OU compared to placebo treatment at Day 29 on pre-specified sign and symptom
endpoints in subjects with moderate to severe DES.